Clinical Neuroscience

[Molecular characterization of the T cell receptor in experimental allergic encephalomyelitis and multiple sclerosis - new therapeutical approaches]

KÁLMÁN Bernadett1, LUBLIN D. Fred2

NOVEMBER 20, 1993

Clinical Neuroscience - 1993;46(11-12)

[The authors review here the most recent literature on experimental allergic encephalomyelitis and multiple sclerosis, focusing on the efferent branch of the immune response. They attempt to describe the molecular characteristics of the myelin antigen specific T cell receptors. Identification of the most distinct properties of the disease mediating cells may not only provide clues to the etiology of MS, but also opens new avenues to specific therapeutical approaches.]

AFFILIATIONS

  1. Országos Ideg- és Elmegyógyászati Intézet, Budapest
  2. Thomas Jefferson University, Philadelphia

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[In Memoriam György Bekény]

HORVÁTH Sándor

[After a life of struggle and success, and after a serious illness borne with dignity and discipline, death took him at the age of seventy-eight. Even in the last years of his life, ill but tireless, he served his vocation with his knowledge: healing and teaching; patients and interested students; the Clinic. Shortly before his death, he completed his last scientific work, The History of Hungarian Neurology.]

Clinical Neuroscience

[The illogical therapy]

SZIRMAI Imre, SUREK György, KAMONDI Anita, MAGYAR Hedvig, JUHÁSZ Csaba

[Most of the causative pathological factors in ischemic cerebrovascular events cannot be recognized during the acute stage of the disease partly because of to the complexity of biophysical model of cerebral microcirculation, partly because the causative factors in this model cannot be confidently weighted. Clinical diagnoses on cerebral circulation disorders are based on the fundamental causes of the disorders. Evoking factors are hypotheses, consequently therapies are directed to hypotheses. The mathematical model of cerebral microcircualtion is mondeterministic. The interactions between vascular factors and blood fluidity can be roughly estimated. Judging the therapeutic efficacy is hindered by the nondeterministic disease model, the indefinite clinical clues, their individual variations, heterogenous diagnostic groups, and tendency of spontaneous restoration of symptoms. Non-specific drugs are used to treat cerebral ischemia, and trials making use of monotherapies have failed to change the life expectancy or the clinical course of ischemic patients. The acute stage of the disease cannot be defined and because of the incompleteness of clinical indicators „stroke prevention" appeares to be ambiguious. Therefore, the nature of the treatment of ischemic cerebrovascular disease is at present based on trial and error.]

Clinical Neuroscience

[Experimential allergic encephalomyelitis multiplex sclerosis!]

KAPÓCS Gábor

[T-lymphocytes and molecular engineering]

Clinical Neuroscience

[Transcranial doppler of extracranial stenosis in internal carotid artery]

NAGY Valéria, BEDŐ György

[Endeavours were made to determine why mean velocity and pulsatility index changes in middle and anterior cerebral artery are caused by the unilateral occlusion of the internal carotid artery or by severe stenosis. The transcranial Doppler method is suitable for judgingre pathologic intracranial blood flow conditions, especially when data are compared to those of healthy conditions.]

Clinical Neuroscience

[Imaging of the lumbar synoval cysts]

PATAY Zoltán, TOURNADE Alain, BALÉRIAUX Danielle, TAJAHMADY Taghy, BERKY Mihály

[Lumbar synovial cysts are infrequent but characteristic manifestations of the commonly encountered but rather complex degenerative disorders affecting the lumbar zygapophyseal joints. The anatomical disposition of the different components of the lumbar motion segment, their sensory innervation and their topographic relationship with the neighbouring nerve structures explain why the neurogical manifestations of these affections, as well as of other articular disorders, cannot always be distinguished from those of discal origin. However, modern imaging methods allow the resolution of the radiological and consequently of the clinical differential diagnostic problems. The systematic use of computed tomography and magnetic resonance imaging in the evaluation of low back pain syndromes has resulted in the recognition and precise description of the practically pathognomonic „radiological syndrome” of the synovial cysts of the lumbar zygapophyseal joints.]

All articles in the issue

Related contents

Clinical Neuroscience

[Consensus statement of the Hungarian Clinical Neurogenic Society about the therapy of adult SMA patients]

BOCZÁN Judit, KLIVÉNYI Péter, KÁLMÁN Bernadette, SZÉLL Márta, KARCAGI Veronika, ZÁDORI Dénes, MOLNÁR Mária Judit

[Background – Spinal muscular atrophy (SMA) is an autosomal recessive, progressive neuromuscular disorder resulting in a loss of lower motoneurons. Recently, new disease-modifying treatments (two drugs for splicing modification of SMN2 and one for SMN1 gene replacement) have become available. Purpose – The new drugs change the progression of SMA with neonatal and childhood onset. Increasing amount of data are available about the effects of these drugs in adult patients with SMA. In this article, we summarize the available data of new SMA therapies in adult patients. Methods – Members of the Executive Committee of the Hungarian Clinical Neurogenetic Society surveyed the literature for palliative treatments, randomized controlled trials, and retrospective and prospective studies using disease modifying therapies in adult patients with SMA. Patients – We evaluated the outcomes of studies focused on treatments of adult patients mainly with SMA II and III. In this paper, we present our consensus statement in nine points covering palliative care, technical, medical and safety considerations, patient selection, and long-term monitoring of adult patients with SMA. This consensus statement aims to support the most efficient management of adult patients with SMA, and provides information about treatment efficacy and safety to be considered during personalized therapy. It also highlights open questions needed to be answered in future. Using this recommendation in clinical practice can result in optimization of therapy.]

Clinical Neuroscience

Matrix metalloproteinases and their tissue inhibitors in relapsing remitting multiple sclerosis: Possible markers and treatment agents

SANLI Arzu, OZTURK Musa, SOYSAL Aysun, DOVENTAS Yasemin, BASOGLU Fulya, GOZUBATIK-CELIK R. Gokcen, BAYBAS Sevim

Matrix metalloproteinases (MMPs), which are synthesized by many cell groups and responsible for the destruction of matrix proteins, and endogen tissue inhibitors of MMPs (TIMPs) have a role in the pathogenesis of Multiple Sclerosis (MS) by affecting the blood-brain barrier. We aimed to investigate the role of MMPs and TIMPs in the immunopathogenesis and in the course of multiple sclerosis (MS). We enrolled 25 relapsing remitting MS patients, who had a definite MS diagnosis according to McDonald criteria and 25 healthy subjects similar for age and gender as control group. MMP-9- and TIMP-1 levels were measured twice in patient group (one time during an attack and one in remission) and once in healthy subjects. MMP-9- and TIMP-levels of patients during attack and remission period and MMP-9/TIMP-1 ratio were found significantly higher than in the control subjects. In patient group MMP-9 and TIMP-1 levels and MMP-9/TIMP-1 ratio during attacks were not significantly different than during remission period. However, when subdivided according to their number of attacks, patients with 2 attacks had significantly higher levels during attack period comparing to remission period (p<0.05); in case of patients with more than 2 attacks did not have a statistically significant difference in attack and remission periods. Matrix metalloproteinases are important actors in MS immunopathogenesis, particularly in the early period and inhibitor agents for these enzymes can be used as a treatment option.

Clinical Neuroscience

Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias

BALÁZS Nóra , BERECZKI Dániel, KOVÁCS Tibor

In aging societies, the morbidity and mortality of dementia is increasing at a significant rate, thereby imposing burden on healthcare, economy and the society as well. Patients’ and caregivers’ quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer’s therapy for approximately two decades and over the years, more and more experience has been gained on their use in non-Alzheimer’s dementias too. The aim of our work was to provide a comprehensive summary about the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s and non-Alzheimers’s dementias.

Clinical Neuroscience

[Family planning in multiple sclerosis: conception, pregnancy, breastfeeding]

RÓZSA Csilla

[Family planning is an exceptionally important question in multiple sclerosis, as women of childbearing age are the ones most often affected. Although it is proven that pregnancy does not worsen the long-term prognosis of relapsing-remitting multiple sclerosis, many patients are still doubtful about having children. This question is further complicated by the fact that patients – and often even doctors – are not sufficiently informed about how the ever-increasing number of available disease-modifying treatments affect pregnancies. Breastfeeding is an even less clear topic. Patients usually look to their neurologists first for answers concerning these matters. It falls to the neurologist to rationally evaluate the risks and benefits of contraception, pregnancy, assisted reproduction, childbirth, breastfeeding and disease modifying treatments, to inform patients about these, and then together come to a decision about the best possible therapeutic approach, taking the patients’ individual family plans into consideration. Here we present a review of relevant literature adhering to international guidelines on the topics of conception, pregnancy and breastfeeding, with a special focus on the applicability of approved disease modifying treatments during pregnancy and breastfeeding. The goal of this article is to provide clinicians involved in the care of MS patients with up-to-date information that they can utilize in their day-to-day clinical practice. ]

Clinical Neuroscience

[Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach]

VÉCSEI László

[The clinical boundaries between the relapsing and progressive course of multiple sclerosis are often indistinct. Despite the variable patterns of evolution, there are no biological reasons for discerning different multiple sclerosis phenotypes. Indeed, both primary progressive and secondary forms of the disease share similar pathological features in respect of the extent of inflammatory infiltrates, axonal damage, and cortical demyelination. The data indicating that primary progressive multiple sclerosis is preceded by an asymptomatic relapsing remitting phase. The proposed definition of secondary progressive multiple slcerosis, the attainment of at least EDSS of 4 is required to mark the transition to the progressive phase. Therefore, the clinical progress can be uncovered in the early phase of the disease. Furthermore, a continuous progression independent of relapsing activity is commonly observed during the relapsing remitting phase. A continuous smouldering process underpins the subtle clinical deterioration, which stands out as an important unmet treatment target. Concerning cognitive dysfunction of the patients pro-inflammatory cytokines have been associated with worse cognition in active multiple sclerosis, and this inflammatory milieu could also contribute to altered mentation during relapses. Therefore, long before people with multiple sclerosis become physically disabled, they have usually acquired hidden disabilities related to cognitive impairment. Silent progression appears during the relapsing remitting phase and it associates with brain atrophy. This suggests that the same process that underlies secondary progressive multiple sclerosis likely begins far earlier than is generally recognized. This supports a unitary view of multiple sclerosis biology. ]